Advertisement

Better Buy: Amgen vs. Mirati Therapeutics

Better Buy: Amgen vs. Mirati Therapeutics

Investors looking for biotech stocks to buy will notice lots of buzz around Amgen (NASDAQ: AMGN) and Mirati Therapeutics (NASDAQ: MRTX) lately. Mirati Therapeutics recently reported impressive interim results from a clinical trial with advanced-stage cancer patients and its lead candidate, adagrasib. This is a potential first-in-class treatment for lung cancer patients with aggressive tumors driven by mutated KRAS proteins.